Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...
Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...
BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp, a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood ...
Labcorp plans to offer Roche’s recently FDA-cleared blood test to assess early signs of Alzheimer’s disease and other causes of cognitive decline for patients 55 years and older. The blood test, which ...
(RTTNews) - Labcorp (LH) Wednesday has announced a significant expansion of its precision oncology offerings with two advanced diagnostic solutions to improve cancer detection and treatment decisions.
Labcorp, one of the country’s largest providers of diagnostic medical testing services, announced today that it will offer the only blood test cleared by the U.S. Food and Drug Administration to aid ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min As the number of Americans at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback